Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19

Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Arch Med Res
Glavni autori: Saha, Abinit, Sharma, Ashish Ranjan, Bhattacharya, Manojit, Sharma, Garima, Lee, Sang-Soo, Chakraborty, Chiranjib
Format: Artigo
Jezik:Inglês
Izdano: IMSS. Published by Elsevier Inc. 2020
Teme:
Opinion
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7241374/
https://ncbi.nlm.nih.gov/pubmed/32482373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.arcmed.2020.05.009
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items